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Background: Due to the paucity of novel antibiotics, colistin has become a last resort antibiotic for treating multidrug
resistant bacteria. Colistin acts by binding the lipid A component of lipopolysaccharides and subsequently disrupting the
bacterial membrane. The recently identified plasmid-encoded MCR-1 enzyme is the first transmissible colistin resistance
determinant and is a cause for concern for the spread of this resistance trait. MCR-1 is a phosphoethanolamine transferase
that catalyzes the addition of phosphoethanolamine to lipid A to decrease colistin affinity.
Results: The structure of the catalytic domain of MCR-1 at 1.32 Å reveals the active site is similar to that of related
phosphoethanolamine transferases.
Conclusions: The putative nucleophile for catalysis, threonine 285, is phosphorylated in cMCR-1 and a zinc is present at a
conserved site in addition to three zincs more peripherally located in the active site. As noted for catalytic domains of
other phosphoethanolamine transferases, binding sites for the lipid A and phosphatidylethanolamine substrates are not
apparent in the cMCR-1 structure, suggesting that they are present in the membrane domain.Background
The increasing prevalence of antibiotic resistance among
bacterial Gram-negative pathogens is a serious threat to
global health. A particular problem is related to the
spread of multidrug resistant Gram-negative bacterial
infections belonging to the enterobacterial family that
are responsible for the highest number of infections for
human kind. The rapid increase in carbapenem-resistant
Enterobacteriaceae that produce carbapenemase en-
zymes, such as KPC and NDM [1], is of special interest.
Due to the paucity of novel antibiotics, polymyxins (co-
listin, polymyxin B), although introduced in the 1950s,
are gaining a renewed interest for treating infections due
to said multidrug-resistant infections. Polymyxins are
cationic polypeptides [2] that act by binding to the lipid
A moiety of bacterial lipopolysaccharides (LPS), subse-
quently disrupting the bacterial membrane.
Acquired and chromosome-encoded resistance to co-
listin has been reported among Gram-negative bacteria* Correspondence: timothyp@bcm.edu
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spp., are intrinsically resistant to colistin [3]. The most
common mechanism of acquired resistance involves
modification of the LPS component of the outer mem-
brane. Specifically, resistance occurs due to modification
of the 1’ and 4’ phosphate groups of lipid A to neutralize
the negative charge and reduce binding of the positively
charged colistin [3, 4]. The phosphates are modified with
4-aminoarabinose by the aminoarabinose transferase
ArnT or by the addition of phosphoethanolamine (PEA)
by PEA transferase enzymes (Fig. 1) [5–7]. Chromosome-
encoded and acquired resistance to polymyxins is associ-
ated with mutations found in genes for two-component
regulatory systems and result in expression of the transfer-
ase enzymes that modify LPS [3, 4].
The X-ray structures of an ArnT transferase as well
as the catalytic domain of the Neisseria meningitidis
(LptA) and Campylobacter jejuni (EptC) PEA transfer-
ases have been determined [8–10]. ArnT is a
membrane protein with a periplasmic domain and is
a member of the GT-C family of glycosyltransferases,
while the PEA transferases have a membrane-
spanning domain and a periplasmic catalytic domain
[8–10]. The catalytic domain of the LptA and EptCicle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Fig. 1 Structure of lipid A of E. coli showing reaction catalyzed by MCR-1. Phosphatidylethanolamine’s R1 and R2 groups are constituted of acyl
chains. The phosphoethanolamine moiety that is transferred from phosphatidylethanolamine to lipid A is shown in red. In this reaction, the
transfer has been shown to occur to the 4’ position of lipid A, however, transfer can also occur to the 1’ position
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members of the sulfatase group with a fold similar to
alkaline phosphatase [9, 10].
Very recently, a plasmid-encoded LPS-modifying en-
zyme, named MCR-1, that provides colistin resistance
has been reported from Enterobacteriaceae in China
[11]. This is an additional source of concern since it is
the first transferrable resistance to polymyxin antibi-
otics. It raises the specter of transferable pan-drug re-
sistance in Enterobacteriaceae. Indeed, there are also
recent reports of the spread of the same mcr-1 gene
worldwide in community- and hospital-acquired patho-
gens in humans and in animals [12–16]. The MCR-1 en-
zyme is 41 % and 40 % identical to the PEA transferases
LptA and EptC, respectively, and sequence comparisons
suggest the active-site residues are conserved [11]. Here,
we report the X-ray crystal structure of the soluble,
periplasmic catalytic domain of the MCR-1 enzyme de-
termined at 1.32 Å resolution. The fold of the MCR-1
catalytic domain is similar to that of the LptA and EptC
transferases, as expected based on sequence homolo-
gies. In addition, many of the presumed active-site resi-
dues are conserved, although the number and position
of active site zinc ions differ among the structures. The
position of binding sites for lipid A and phosphatidyl-
ethanolamine are not apparent in the catalytic domain
structure, suggesting that they are present in the mem-
brane domain.Results
Crystal structure of the catalytic domain of MCR-1
In order to examine the structural and molecular fea-
tures of the catalytic domain of MCR-1 (cMCR-1, resi-
dues 215–541), we determined its X-ray crystal structure
(Fig. 2). Two soluble domain truncations of cMCR-1,
mcr-1Δ1–214, and mcr-1Δ1–236, were produced with an N-
terminal His6-tag sequence (see Methods). It was found
that the mcr-1Δ1–214 construct produced sufficient
amounts of protein for purification and crystallographic
studies. Diffraction-quality crystals of cMCR-1Δ1–214
were obtained only after cleavage of the N-terminal
His6-tag. Excluding the His6-tag, the cMCR-1Δ1–214 pro-
tein consists of 330 residues with an estimated molecu-
lar weight of 36.8 kDa. The crystals diffracted to 1.32 Å
resolution and the phases of cMCR-1 were determined
by single anomalous diffraction techniques using zinc as
the anomalous scatterer. The cMCR-1 protein crystal-
lized in the P43212 space group with one molecule in the
asymmetric unit (Table 1). The determined structure
shows a well-defined electron density for a total of 324
residues spanning from Asp218 to Arg541.
cMCR-1 is a globular protein with an overall hemi-
spherical shape and a centrally located β-sheet com-
posed of seven β-strands sandwiched between α-helical
structures (Fig. 2). The catalytic domain of MCR-1
assumes the α/β/α fold characteristic of the alkaline
phosphatase superfamily. The first 23 residues of cMCR-
Fig. 2 Structure of the catalytic domain of MCR-1 phosphoethanolamine transferase. Secondary structure elements are depicted as a ribbon
model and colored in cyan (helices), purple (strands), and salmon (loops). Additionally, the phosphothreonine 285 is represented in sticks. Right,
rotated 90 °, a view of the characteristic alkaline phosphatase α/β/α fold of cMCR-1
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the surface of the protein. Although unstructured, this
region was found to be important for the expression and
purification of the cMCR-1 protein in that the removal
of this region (MCR-1Δ1–236 construct) resulted in aggre-
gation and poor purification yields (data not shown).
Upon inspection of the electron density map, a
residual density was observed protruding from the side
chain hydroxyl oxygen of Thr285. The biological func-
tion of the enzyme and the tetrahedral shape of the
density suggested the presence of a phosphate group co-
valently attached to the side-chain oxygen resulting from
phosphorylation of Thr285 (Figs. 3 and 4). The phos-
phate group was then modeled into this density followed
by positional and occupancy refinement, and validation
by using difference density maps. The average occupancy
and B-factor of the phosphate group atoms following the
refinement were 0.97 and 9.0 Å2, respectively, indicating
that nearly all of the enzyme was in the phosphorylated
state. The phosphothreonine 285 is located centrally on
the flat surface of the hemisphere opposite to the start-
ing β-strand β1, at the N-terminal end of the α3 helix
(Fig. 2). Surrounding the phosphothreonine are three
zinc ions, which were identified by the anomalous signal
and further confirmed by difference maps (Figs. 3 and
4). Based on previous studies of PEA transferases, the
presence of phosphorylated threonine, and the zinc
binding sites, this region of the catalytic domain was
inferred as the active site of MCR-1 [9, 10].
The catalytic domain of MCR-1 contains six cysteine
residues and the cysteines form three disulfide bonds
between residues Cys281/Cys291, Cys356/Cys364, andCys414/Cys422 (Fig. 5a). The location of the catalytic
domain of full-length MCR-1 is presumably on the peri-
plasmic face of the cytoplasmic membrane, based on the
predicted five membrane spanning helices in the N-
terminal transmembrane domain of the protein and pre-
vious results with PEA transferases. The cMCR-1Δ1–214
construct used for protein expression, however, lacks the
transmembrane domain and is expressed in the reducing
environment of the cytoplasm. It is possible that, upon
cell lysis for purification, the cysteines become oxidized
to form the disulfide bonds. The Cys281/Cys291 disul-
fide bond bridges a loop region with the α3-helix on
which the phosphothreonine is located. The Cys356/
Cys364 bond is located in an extended loop region that
connects the β4-strand and α8-helix and the Cys414/
Cys422 disulfide bond is positioned near each end of the
α11-helix (Fig. 5a).
Active-site and protein surface zinc binding sites
There are ten zinc ions in total per protein molecule in
the crystal structure of cMCR-1. Three zinc ions (Zn1, 2,
and 3, with average occupancies of 0.97, 0.88, and 0.93
and B-factors of 6.6, 7.1, and 8.7 Å2, respectively) are lo-
cated in the active site of the enzyme as well as an add-
itional zinc ion (Zn4, with average occupancy of 0.95 and
B-factor of 6.8 Å2) that is shared between two adjacent
protein molecules in the crystal lattice (Fig. 4). Zn1 is bur-
ied in the active site of MCR-1 and is tetrahedrally coordi-
nated by a phosphate oxygen of phosphothreonine-285 as
well as the conserved residues Asp465, Glu246, and
His466 (Fig. 4). Zn2 is bound by a phosphate oxygen of
phosphothreonine-285, Nε2 atom of His395, and three
Table 1 Data collection, phasing, and refinement statistics for
the structure of cMCR-1
cMCR-1 (PDB ID 5K4P)
Data collection
Space group P43212
Cell dimensions
a, b, c, Å 59.1, 59.1, 186.7
α, β, γ, ° 90, 90, 90
Wavelength, Å 1.00
Resolution, Åa 49.9–1.32 (1.39–1.32)
Rmerge 0.057 (0.491)
Rmeas 0.079 (0.892)
Rpim 0.055 (0.552)
I/s(I) 9.6 (1.7)
CC1/2 0.996 (0.547)
Completeness, % 100 (100)
Redundancy 14.7 (11.7)
Refinement
Resolution, Å 49.9–1.32 (1.39–1.32)
No. reflections 78753
Rwork/Rfree 0.1464/0.1732
No. atoms 2935
Protein 2541
Ligand/ion (D-sorbitol/zinc) 12/10
Water 368
B factors, Å2
Protein 12.1
Zinc 10.8
D-sorbitol 11.3
Water 25.1
Root-mean-square deviations
Bond lengths, Å 0.007
Bond angles, ° 0.878
MolProbity clash score 1.00
aValues in parentheses are for highest resolution shell
Fig. 3 Structure of the active-site phosphothreonine with associated
zinc ions. The phosphothreonine (TPO285) is represented as a
yellow-orange-red stick model and the zinc ions (ZN1, ZN2, ZN3,
and ZN4) that surround the phosphothreonine are shown as slate
blue spheres. The 2Fo − Fc simulated annealing difference map of
the final refined model contoured at σ = 4.0 is shown as a gray
mesh. ZN4 is also coordinated by Glu405 from a neighboring
molecule in the crystal. The neighboring MCR-1 protein is colored
white and labeled with the prefix #2
Fig. 4 Representation of the zinc ions identified in the active site of
cMCR-1. Zinc ions are shown as slate blue spheres and active-site
residues are represented in stick model. In yellow, is one MCR-1 (#1)
molecule, and in white, is another MCR-1 (#2) molecule located
adjacent to the first one. ZN4 from the second molecule is
positioned at the interface and is shared by the two molecules.
Structural water molecules are labeled and hydrogen bonds and
zinc interactions are shown with dashed lines
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embedded in the enzyme and is tetrahedrally coordinated
by four water molecules. The waters that coordinate Zn2
and Zn3 are connected to the protein by an extensive
hydrogen bond network. For example, water-103, involved
in the binding of Zn2, is hydrogen bonded to the side
chain oxygen of Glu246 and the side chain Nδ2 of Asn329
(Fig. 4). Water-103 is also hydrogen bonded to water-69,
which also interacts with Zn2 (Fig. 2). In addition, water-
367 forms a bridge between Zn2 and Zn3. Another Zn3
ligand, water-368, forms a hydrogen bond to Nε2 of
His478 and is also hydrogen bonded to water-366 and
water-348, each of which is a Zn3 ligand (Fig. 4).Therefore, the waters that coordinate Zn2 and Zn3 are
part of a network of hydrogen bonds that link the zinc
atoms to each other and the protein. Zn4 is also near the
active site and interacts with phosphothreonine-285 and
water molecules as well as Glu405 from a neighboring
cMCR-1 molecule so that Zn4 serves as a bridge in a crys-
tal contact (Fig. 4). The remaining zinc ions are scattered
over the surface of the protein and are mainly coordinated
Fig. 5 Comparison of the crystal structures of the catalytic domains of MCR-1 (a), EptC (C. jejuni) (PDB code 4TN0) (b), and LptA (N. meningitidis)
(PDB code 4KAY) PEA transferases and their conserved active-site residues (c). Top panels – All of the enzymes adopt a similar fold and the
active-site threonine is in phosphorylated form. The active site phosphothreonine is labeled for each enzyme. Disulfide bonds are shown as
space-fill spheres and the numbers of the participating residues are labeled. Bottom panels – Representative active-site residues are shown in stick
model together with interacting zinc ions represented as slate blue spheres. The dashed lines represent interacting distances < 3.3 Å. The MCR-1
active site has three zinc ions bound compared to one zinc for EptC and two zincs for LptA. The MCR-1 zinc ion that is coordinated by
phosphothreonine-285, Glu246, Asp465, and His466 is conserved in EptC and LptA
Table 2 Minimum inhibitory concentrations (μg/mL) for E. coli
containing a plasmid encoding N-terminally His-tagged wild-
type MCR-1 and MCR-1 T285A
E. coli + Colistin Polymyxin B
pET28a (empty vector) 0.032 0.032
mcr-1 pET28a 8.0 6.0
mcr-1 T285A pET28a 0.125 0.092
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zinc ions associated with the MCR-1 structure is likely
due to the fact that the enzyme crystallized in a condition
containing 200 mM zinc acetate (see Methods).
Test of the effect of a Thr285Ala substitution on MCR-1-
mediated resistance
If Thr285 is the catalytic nucleophile, mutation of this
residue would be expected to greatly decrease MCR-1
function. This was tested by mutating this residue to ala-
nine in a plasmid encoding the full-length mcr-1 gene
with an N-terminal His-tag and measuring the minimum
inhibitory concentration of colistin and polymyxin B.
The strain containing wild-type mcr-1 exhibited mini-
mum inhibitory concentrations (MICs) of 8.0 and 6.0
μg/mL for colistin and polymyxin B, respectively, com-
pared to a MIC of 0.032 μg/mL for the control strain
containing the plasmid without mcr-1 (Table 2). Muta-
tion of Thr285 to alanine lowers the colistin and poly-
myxin B MICs to near the control levels (Table 2).
Similar results were obtained with the wild-type MCR-1
gene and T285A mutant without an N-terminal His-tag,
indicating the His-tag does not impair in vivo MCR-1
function. To assess whether the T285A mutant is
expressed and directed to the membrane, immunoblot
analysis was performed using an anti-His-tag antibody(Fig. 6). The immunoblot suggests that the T285A muta-
tion does not affect the expression or the membrane loca-
tion of the MCR-1 protein. Altogether, these results
indicate that Thr285 is important for MCR-1 function and
is consistent with it serving as the catalytic nucleophile.
Structure homology between cMCR-1, cEptC and cLptA
The structure coordinates of MCR-1 were submitted to
the DALI server for comparison with other known pro-
tein structures. The closest structural homologues are
the PEA transferases EptC from Campylobacter jejuni
and LptA from Neisseria meningitidis [9, 10]. These en-
zymes had previously been noted as homologues of
MCR-1 based on primary amino acid sequence hom-
ology [11]. An amino acid sequence alignment of MCR-
1 with EptC and LptA is shown in Additional file 1:
Figure S1.
Fig. 6 Immunoblot indicating expression levels and localization of
N-terminal His-tagged, full-length wild-type MCR-1 (lane 1–4) and
T285A (lane 5–8) mutant. L whole cell lysis, P pellet, S soluble, D
detergent-soluble membrane fraction. Lane 9 (+) purified His-MCR-1
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and share the majority of their secondary structures
(Fig. 5a, b). The cMCR-1 and cEptC structures have a
root-mean-square deviation (RMSD) of 0.861 Å between
217 residues when matching Cα atom pairs. Both
cMCR-1 and cEptC contain three disulfide bonds. The
MCR-1 Cys281/Cys291 disulfide bond near the catalytic
Thr265 is positioned similarly to the cEptC Cys262/
Cys272 bond and the cMCR-1 Cys414/Cys422 bond that
is distant from the active site is equivalent to the cEptC
Cys377-Cys385 pair (Fig. 5). The cMCR-1 Cys356/
Cys364 pair has no equivalent in cEptC. This pair re-
sides in an extended loop between the β4 strand and the
α8 helix in cMCR-1, and this loop is significantly shorter
and lacking a disulfide bond in cEptC (Fig. 5). In
addition, cEptC contains a Cys312/Cys316 disulfide
bond near the active site that is also conserved in the
cLptA enzyme but is not present in cMCR-1 (Fig. 5).
The functional consequences of these differences are
currently not known.
The RMSD between 237 Cα atom pairs of the structures
of cMCR-1 and cLptA is 0.875 Å. This RMSD is slightly
higher than that of cMCR-1/cEptC, but nevertheless, the
structures are very similar. The disulfide-bonding pattern
of these two enzymes varies in that cLptA has ten cysteine
residues (four more than cMCR-1) that form five disulfide
bonds compared to only three in cMCR-1. The Cys281/
Cys291, Cys414/Cys422, and Cys356/Cys364 disulfide
bonds found in cMCR-1 all have equivalents in cLptA
(Fig. 5). As noted above, the cMCR-1 Cys356/Cys364 pair
is in an extended loop between the β4 and the α8 helix
and this loop is truncated in cEptC. Similar to cMCR-1,
an extended loop is present in this region in cLptA and
contains a disulfide bond (Cys348/Cys353); however, the
conformation of this loop is different than that in cMCR-1
(Fig. 5). Of the two additional disulfide pairs found in
cLptA but not in cMCR-1, one is Cys327/Cys331, which is
near the active site and has an equivalent in cEptC. In
contrast, the second additional cLptA disulfide bond
(Cys499/Cys540) has no equivalent in cEptC or cMCR-1.
It is located towards the C-terminus of cLptA, where it
connects two α-helices. This region is an unstructured ex-
tended loop in cMCR-1.The active sites of MCR-1, EptC, and LptA are highly
conserved (Fig. 5). All three enzymes contain a threo-
nine residue that likely acts as a nucleophile for attack
on the phosphate of the donor molecule phosphatidyl-
ethanolamine. This threonine is phosphorylated in all
three structures (Fig. 5). A bound zinc (Zn1) is coordi-
nated by the phosphothreonine in MCR-1 and this zinc
is conserved in the structures of cEptC and cLptA
(Fig. 5). Glu246, Asp465, and His466 also coordinate this
zinc in cMCR-1 and these residues are conserved in
cEptC and cLptA. Structural equivalents of this zinc and
the coordinating residues are also conserved in alkaline
phosphatase. Therefore, this zinc site appears to be a
core component of this family of enzymes and it has
been proposed to stabilize the alkoxide of the active-site
threonine for nucleophilic attack on the phosphate of
the phosphatidylethanolamine substrate for LptA [9].
The cMCR-1 His478 and His395 residues are also con-
served in cEptC and cLptA (Fig. 5). In the cMCR-1
structure, His395 coordinates an additional zinc (Zn2) in
the active site, while His478 does not contact zinc. In
the cLptA structure, the His395 and His478 equivalent
residues coordinate the second zinc (Fig. 5). The differ-
ences between cMCR-1 and cLptA for the His478 resi-
due are due to the altered position of the second zinc in
cMCR-1 compared to cLptA (Fig. 5). The cEptC active
site contains only one zinc, so neither of these His resi-
dues coordinates zinc in the cEptC structure. Finally, as
noted above, MCR-1 contains a third zinc that contacts
phosphothreonine-285 but is not coordinated by other
MCR-1 residues and a fourth zinc that is bridged by a
neighboring MCR-1 molecule in the crystal lattice
(Figs. 4 and 5). Neither of these zincs is found in the
cLptA or cEptC structures [9, 10]. The peripheral loca-
tion of these zincs suggests they may not play a role in
catalysis and may be a function of the high zinc concen-
tration in the crystallization conditions for MCR-1. The
binding of multiple zinc ions by both cLptA and particu-
larly cMCR-1, compared to cEptC, is likely due to in-
creased zinc concentrations during crystallization. The
functional significance of the additional zinc sites in
cMCR-1 awaits further study.
Discussion
PEA transferase enzymes, such as MCR-1, catalyze the
lipid-to-lipid transfer of PEA from phosphatidylethanol-
amine to the 1’ or 4’ phosphate positions of lipid A [7].
The catalytic domain of MCR-1 has the alkaline phos-
phatase superfamily fold and there is conservation of
several residues in the active site compared to alkaline
phosphatase. The mechanism of MCR-1 and other PEA
transferases is not known, although it may proceed simi-
larly to alkaline phosphatase [9]. The Zn1 site in MCR-1
is common to PEA transferases and alkaline phosphatase
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alkoxide form of an active site serine for nucleophilic at-
tack on the phosphate of phosphate monoesters [17, 18].
In MCR-1, this zinc may stabilize the alkoxide form of
the structurally analogous Thr285 for nucleophilic attack
on the phosphate of phosphatidylethanolamine to create
an intermediate with Thr285 linked to PEA. Binding of
lipid A in an appropriate position for nucleophilic attack
on the lipid A 1’ or 4’ phosphate on the phosphate of
the Thr285-PEA intermediate could then transfer the
group to lipid A. As discussed below, however, there are
no obvious binding sites for phosphatidylethanolamine
and lipid A on the catalytic domain and insights into the
catalytic mechanism await the structure of the entire
MCR-1 protein in the presence of substrates or substrate
analogues.
In support of the catalytic threonine as a nucleophile
for attack on a phosphate, this residue is phosphorylated
in the cMCR-1, cLptA, and cEptC structures [9, 10].
This is unlikely to be a true intermediate, however, as
there is no indication of electron density for ethanol-
amine attached to the phosphate. This may be due to ex-
pression of the protein without the membrane domain
and thus it is not localized to the membrane where the
lipid substrates reside.
Although the structure of cMCR-1 reveals active site
similarities to alkaline phosphatase and a putative
nucleophilic threonine, the binding sites for the lipid A
and phosphatidylethanolamine substrates are not
obvious. The MCR-1 catalytic domain has a hemispheric
shape and the zinc binding pocket containing
phosphothreonine-285 resides on a relatively flat surface.
The structure of the ArnT aminoarabinose transferase
that also uses lipid A as substrate and, like the PEA
transferases, acts at the 1’ and 4’ phosphate positions of
lipid A, was recently determined [8]. The aminoarabi-
nose transferred by ArnT to the lipid A phosphates is
provided by the lipid carrier undecaprenyl phosphate.
Although ArnT is not homologous to the PEA transfer-
ases and the structures are not expected to be con-
served, it is a lipid-to-lipid transferase with similar
substrates and a similar function as PEA transferases.
The ArnT apo-structure revealed cavities that could po-
tentially bind the lipid substrates and a structure with
undecaprenyl phosphate indicated a cavity that binds
this substrate, thereby also suggesting the binding site of
lipid A resides in another large cavity [8]. The lipid bind-
ing cavities of ArnT reside both within the membrane-
spanning section and near the periplasmic interface [8].
In contrast, no such cavities are apparent in the cMCR-1
structure. An important difference between the ArnT
and cMCR-1 structure experiments is that the entire
ArnT protein structure was determined, including the
membrane portion containing 13 membrane-spanninghelices while only the periplasmic domain structure of
MCR-1 was solved. It is likely that the membrane do-
main of MCR-1, with five predicted membrane spanning
helices, contributes to the lipid binding sites, which may
reside in the interface between domains as suggested
previously for LptA [8, 9].
Conclusions
The high-resolution structure of the polymyxin resist-
ance enzyme MCR-1 has been determined at 1.32 Å
resolution. The structure of the catalytic domain of
MCR-1 reveals conservation of structure, particularly in
the active site, with other PEA transferases [9, 10]. PEA
transferases are an interesting drug target in that they
are present in a wide range of Gram-negative bacteria
and play a role in modifying the bacterial lipopolysac-
charide in response to environmental conditions, includ-
ing host defenses [7]. The structural conservation of the
MCR-1 active site with other PEA transferases suggests
that inhibitors of MCR-1 may also inhibit chromosom-
ally encoded PEA transferases. Such inhibitors would
not only restore polymyxin susceptibility but also modify
the ability of bacteria to avoid host defenses during
pathogenesis.
Methods
Construct design, cloning, protein expression, and MIC
determination
The MCR-1 protein is predicted to consist of a
membrane-spanning domain and a periplasmic catalytic
domain [11]. In order to design a protein expression
construct for the soluble catalytic domain, the mcr-1 se-
quence was retrieved from GI: 817091896 (GeneBank:
AKF16168.1). The TMHMM Server, v2.0 S, was used to
identify the five potential transmembrane regions [19].
Additionally, the ThreaDom server was utilized for pro-
tein domain boundary prediction [20]. The ThreaDom
results suggest that MCR-1 consists of two domains with
domain 1 (N-terminal, transmembrane domain) contain-
ing residues 1–214 and domain 2 (C-terminal, soluble
catalytic domain) consisting of residues 215–541. The
C-terminal domain, confined by residues 215–541, was
submitted to the I-TASSER server for protein structure
and function prediction [21–23]. I-TASSER predicted
that the first 23 residues of the soluble domain consist
of an unstructured loop region with the first secondary
structure (β-strand) starting at residue Arg238. Based on
the aforementioned information, two different con-
structs were generated by PCR amplification of the 215–
541 encoding region (mcr-1Δ1–214 construct) and the
237–541 encoding region (mcr-1Δ1–236 construct) of the
mcr-1 gene. The PCR products were cloned into the
pET28a vector by Gibson assembly for further protein
expression and purification. DNA sequencing of the
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traneous mutations were present.
In order to test the in vivo function of MCR-1 and the
T285A mutant, the full-sized MCR-1 was cloned into
the plasmid pBCKSII. In addition, the full-sized MCR-1
with an N-terminal His-tag was inserted into the
pET28a plasmid. The T265A substitution was intro-
duced into both the wild-type and His-tagged version of
MCR-1 by oligonucleotide-directed mutagenesis. The
DNA sequence of the entire genes was determined to
ensure no extraneous mutations occurred.
Immunoblot analyses were performed with full-length
MCR-1 proteins, including N-terminal His6-tags, and
were detected with anti-His monoclonal mouse antibody
conjugated to horseradish peroxidase (Qiagen, Venlo,
Netherlands, Cat. No./ID 34460; Lot/Batch No.
139306078). In brief, cells were grown at 37 °C with shak-
ing to an OD600 of 0.5. Protein production was induced by
the addition of IPTG to a final concentration of 0.5 mM.
Proteins were expressed at 25 °C with shaking and cells
were harvested after 2 hours of incubation. Cells were
lysed by sonication. The lysate was centrifuged to obtain
the pellet and supernatant, which were used for assaying
the presence of MCR-1 by immunoblotting (Fig. 6). The
membrane fraction was obtained by treating the whole
cell lysate with detergent (30 mM dodecyl maltoside) and
incubating for 2 hours at 25 °C. The soluble and insoluble
fractions were then obtained by centrifugation. The
detergent-soluble fraction was assayed for the presence of
MCR-1 by immunoblotting (Fig. 6).
Polymyxin susceptibility testing was performed with
the full-length proteins that contain the N-terminal His-
tag by determination of MICs using the broth microdilu-
tion method according to the CLSI guidelines [24]. The
E. coli strain BL21(DE3) was used for the susceptibility
testing experiments [25].
Protein expression and purification
Both constructs of the catalytic domain, MCR-1Δ1–214
and MCR-1Δ1–236 (with the inclusion of an N-
terminal His-tag for both constructs), were expressed
in E. coli BL21DE3 cells; 10 mL of overnight culture
was used to inoculate 1 L of LB medium supple-
mented with 30 μg/mL of kanamycin. The cell culture
was then incubated at 37 °C with shaking until it
reached an OD600 of 0.5–0.7; at this point, protein
production was induced by addition of IPTG at a
final concentration of 0.5 mM. The culture was then
incubated at 25 °C for 20 hours. Afterward, the cells
were harvested by centrifugation at 8000 rpm for 40
minutes at 4 °C. The cell pellet was incubated at −20
°C for 4 hours and then resuspended in 20 mL lysis
buffer containing 50 mM phosphate pH 7.4, 400 mM
NaCl, 40 μM MgCl2, and 10 ng/mL DNAse. Cellswere ruptured using a French press and the cell lysate
was centrifuged at 12,000 rpm for 30 minutes. The
supernatant was passed through a 0.22 μm filter and
loaded on a HisTrap FF column (GE Healthcare,
Pittsburg, PA). The proteins were eluted with a linear
gradient of 500 mM imidazole. Protein purity was de-
termined by SDS-PAGE. The protein was concen-
trated using Vivaspin® Turbo 15 centrifugal filters 30
MWCO (Sartorius, Goettingen, Germany). The N-
terminal His-tag was removed by overnight digestion
at 4 °C with His-tagged tobacco etch virus protease at
a molar ratio of 1:50 (protease:protein). The cleaved
sample was again loaded onto a HisTrap FF column
for tobacco etch virus separation. The concentration
of the protein and buffer exchange to 50 mM HEPES
pH 7.2 and 50 mM NaCl was performed with Vivas-
pin® Turbo 15 centrifugal filters 30 MWCO (Sartor-
ius). It should be noted that only one of the proteins
(MCR-1Δ1–214) was stable and gave a sufficient
amount of pure protein for further crystallography
studies. Protein concentration was determined by ab-
sorbance measurements at 280 nm using an extinc-
tion coefficient of 37,735 M−1 cm−1 [26].
Protein crystallization and data collection
Crystal conditions were screened using the vapor dif-
fusion hanging-drop method with 7–8 mg/mL of
protein. Crystallization trials were performed with
versions of the protein both with and without the
His-tag. Drops were set up in 96-well plates at a 1:1
ratio using several commercially available screens,
including PEGs and PACT suites from Qiagen (Velno,
Netherlands), and PEG/Ion and Crystal Screen suites
from Hampton Research (Aliso Viejo, CA). Initial
crystals formed only with the protein that had the
His-tag removed and produced snowflake-shaped
crystals in two conditions: 0.1 M HEPES pH 7.5 and
15 % PEG 20,000 (PEGs suite #30); and 0.2 M zinc
acetate dihydrate, 0.1 M sodium cacodylate trihydrate
pH 6.5, and 18 % PEG 8000 (Crystal Screen #45).
Next, these two conditions were prepared in-house
and used to set 96-well plates with the Additive
Screen™ (Hampton research) following the manufac-
turer’s guidelines. Only the second condition contain-
ing zinc acetate produced single diffraction-quality
crystals in the presence of 3 % w/v D-sorbitol. Crys-
tals were harvested and cryo-protected using a
mixture of paraffin oil and peritone (70:30). Crystals
were flash-cooled in liquid nitrogen before shipment
to the Advance Light Source synchrotron at Berkeley
National Laboratory. A 1.32-Å resolution data set was
collected on beamline 8.2.1 of the Berkeley Center for
Structural Biology in the context of the Collaborative
Crystallography Program.
Stojanoski et al. BMC Biology  (2016) 14:81 Page 9 of 10Data processing, single anomalous diffraction-phasing,
and structure refinement
The crystallography data was processed using the CCP4
suite [27]. The images were processed by iMOSFLM and
data was scaled using SCALA with the anomalous pairs
separated to enable calculation of anomalous difference
maps for the zinc containing crystals [28, 29]. Data were
then input into the CRANK2 pipeline component of the
CCP4 online programs [30]. In brief, free set was defined
using SFtools; followed by heavy atom structure factors
(FA) estimation by SHELXC; substructure determination
with SHELXD; substructure improvement with PEAKMAX
and REFMAC5; hand determination with MAPRO; density
modification with Parrot; model building using Buccaneer
and SHELXE; and, finally, an initial refinement with
REFMAC5 [31–38]. This was followed by manual inspec-
tion and iterative cycles of model building in COOT and
crystallographic refinement (including anisotropic B-
factors) using PHENIX [37, 39, 40]. The final structure was
validated using the PDB_REDO and MolProbity servers
[41, 42]. Alignment and RMSD calculations were per-
formed by the SSM procedure [43]. All structural figures
were generated with the UCSF Chimera graphics program
and the PyMOL Molecular Graphics System (Schrödinger,
LLC, New York, NY) [44].Additional file
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